Why the study?
Malignant cardiac tamponade is life-threatening and requires prompt treatment and effective management to prevent recurrence.
Does intrapericardial bleomycin instillation safely prevent recurrence and improve survival in cancer patients with malignant cardiac tamponade?
Does intrapericardial bleomycin instillation safely prevent recurrence and improve survival in cancer patients with malignant cardiac tamponade?
Intrapericardial bleomycin instillation following pericardiocentesis is a safe and effective procedure for malignant cardiac tamponade, with survival largely dependent on subsequent oncological treatment.
Answers are grounded in this paper and cite their sources.
May support intrapericardial bleomycin in malignant tamponade; leaves open need for randomized confirmation of efficacy and survival predictors.
BACKGROUND: Malignant cardiac tamponade is a life-threatening condition that requires prompt treatment and effective management to prevent recurrence. This paper describes safety and efficacy outcomes after intrapericardial instillation of bleomycin as well as possible predictors of survival. METHODS: We performed a 10-year retrospective, single-center study to evaluate the safety and efficacy of intrapericardial instillation of bleomycin in patients with suspected malignant cardiac tamponade. RESULTS: Intrapericardial instillation of bleomycin was performed in 31 cancer patients (9 men, 22 women) presenting with cardiac tamponade. Non-fatal complications occurred in 3 patients and relapse occurred in 1 patient. Overall survival was less than 10% at the end of the study. Median survival was 104 days (95% CI, 0-251 days). Survival was compared between different groups (defined by primary tumor, type of tumor, TNM stage and results of cytological analysis) with median survival being considerably higher when oncologic therapy was altered afterwards. CONCLUSIONS: The use of intrapericardial bleomycin instillation following pericardiocentesis for malignant cardiac tamponade is a safe procedure with a high success rate. Survival rates depend on further oncological treatment options available.
No takes yet. Share an insight, caveat, or question.
Defruyt et al. (2020) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: